The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study


About this study

The purpose of this study is to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Patients must be less than 22 years of age at the time of study enrollment.

- Patient must have one of the following:

- Patient has known or suspected relapsed/refractory (including primary refractory) AML;

- This includes isolated myeloid sarcoma.

- Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome.

- Patient has known or suspected relapsed ALL that meets one of the following criteria:

- Second or greater B-ALL medullary relapse, excluding KMT2Ar;

- Any first or greater B-ALL medullary relapse involving KMT2Ar;

- Any first or greater T-ALL medullary relapse with or without KMT2Ar;

- Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia;

- Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment related AML.

- All patients and/or their parents or legal guardians must sign a written informed consent.

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/4/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Wendy Allen-Rhoades, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer